Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2015-12-09 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release announcing research and development updates. The document is short (2298 characters) and primarily serves as a regulatory filing to disclose information to the SEC. It does not contain detailed financial statements or comprehensive reports like an annual or interim report. It also does not fit into categories like earnings release, management report, or capital update. Given the nature of Form 6-K filings and the content described, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2015-12-09 English
FORM 6-K
Earnings Release Classification · 95% confidence The document is a Form 6-K filing by BioBlast Pharma Ltd., which is a report of a foreign private issuer submitted to the SEC. It includes a press release announcing the company's financial results for the third quarter ended September 30, 2015. The document is relatively short (2327 characters) and primarily serves to announce the financial results rather than containing the full financial statements or detailed analysis itself. Form 6-K filings typically serve as interim updates or announcements for foreign issuers and often include press releases or other material information. Given the nature of the document as a press release announcement of quarterly financial results and its short length, it fits best under the category of Earnings Release (ER).
2015-11-17 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release announcing the appointment of three new senior executives and key organizational changes. There are no financial statements or detailed financial data present. The document is relatively short (2381 characters) and primarily serves as an announcement of management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, the appropriate classification is MANG.
2015-11-16 English
FORM 6-K
Interim / Quarterly Report Classification · 85% confidence The document is a Form 6-K filing by a foreign private issuer, BioBlast Pharma Ltd., submitted to the SEC. It contains a press release announcing interim results from a phase 2 clinical study and a corresponding presentation. The document is relatively short (2777 characters) and primarily serves to report interim clinical trial results rather than providing comprehensive financial statements or detailed quarterly financial data. Form 6-K filings typically serve as periodic reports for foreign issuers and often include press releases or presentations. Given the content focuses on interim clinical study results and includes a presentation, it aligns best with an Interim / Quarterly Report (IR) category, as it contains substantive interim results information. It is not an Annual Report (10-K), Earnings Release (ER), or purely a presentation (IP) since it includes a press release with interim results. It is not a Regulatory Filing (RNS) because it contains substantive interim results rather than just certifications or notices. Therefore, the best classification is Interim / Quarterly Report (IR).
2015-10-27 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, BioBlast Pharma Ltd., submitted to the SEC. It contains a press release announcing the appointment of a new Chief Corporate Development Officer. There are no financial statements, earnings data, or detailed reports included. The content is primarily an announcement of a management change. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document length is short (2324 characters), and it is not a report or financial statement but an announcement. Therefore, the correct classification is MANG with high confidence.
2015-10-09 English
FORM 6-K
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, BioBlast Pharma Ltd., with the SEC. It contains a press release announcing the appointment of Tom Dubin to the Board of Directors. The content is about a management change and does not include financial statements or detailed financial data. The document length is short (2298 characters), and it is primarily an announcement of a board appointment. Therefore, it fits the category of Board/Management Information (MANG).
2015-09-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.